Entering text into the input field will update the search result below

FDA Ad Com backs Cardinal's Incraft stent

Jun. 13, 2018 7:04 AM ETCardinal Health, Inc. (CAH) StockBy: Douglas W. House, SA News Editor1 Comment
  • The FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee voted 11-4 in favor of approval for Cardinal Health (NYSE:CAH) unit Cordis' INCRAFT AAA Stent Graft System for the treatment of infrarenal aortic aneurysms.
  • The device was CE Mark'd in 2014.
  • Previously: Ad Com June 12 for Cardinal's InCraft stent; shares ahead 6% (May 10)

Recommended For You

About CAH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CAH--
Cardinal Health, Inc.